This cohort study aims to evaluate the validation of general evaluation score in the prediction of hepatocellular carcinoma risk among patients with advanced fibrosis (F3) and cirrhosis (F4) who achieved sustained virological response for hepatitis c virus after direct acting antiviral drugs and determine the group of these patients who require intensified surveillance.
Study Type
OBSERVATIONAL
Enrollment
500
According to Evaluation of GES scores Patient will be classified into three groups based on GES score low risk group (score ≤6 points), intermediate risk group (score 6-7.5 points), and high-risk group (score \>7.5 points)
Egyptian Liver Hospital
Ţalkhā, Dakahlia Governorate, Egypt
Hepatocellular Carcinoma
Number of Participants develop New Hepatocellular Carcinoma
Time frame: 24 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.